Menéndez P R, Roth B M C, Pereira M D, Casal M R, González S J, Feld D B, Santa Cruz G A, Kessler J, Longhino J, Blaumann H, Jiménez Rebagliati R, Calzetta Larrieu O A, Fernández C, Nievas S I, Liberman S J
Instituto de Oncología Angel H. Roffo. Av. San Martín 5481, (1417) Cdad. de Buenos Aires, Argentina.
Appl Radiat Isot. 2009 Jul;67(7-8 Suppl):S50-3. doi: 10.1016/j.apradiso.2009.03.020. Epub 2009 Mar 27.
As part of phase I/II melanoma BNCT clinical trial conducted in Argentina in a cooperative effort of the Argentine Atomic Energy Commission (CNEA) and the Oncology Institute Angel H. Roffo (IOAHR), 7 patients (6 female-1 male) received eight treatment sessions covering ten anatomical areas located in extremities. Mean age of the patients was 64 years (51-74). The treatments were performed between October 2003 and June 2007. All patients presented multiple subcutaneous skin metastases of melanoma and received an infusion containing approximately 14 gr/m(2) of (10)borophenyl-alanine (BPA) followed by the exposition of the area to a mixed thermal-epithermal neutron beam at the RA-6 reactor. The maximum prescribed dose to normal skin ranged from 16.5 to 24 Gy-Eq and normal tissue administered dose varied from 15.8 to 27.5 Gy-Eq. Considering evaluable nodules, 69.3% of overall response and 30.7% of no changes were seen. The toxicity was acceptable, with 3 out of 10 evaluable areas showing ulceration (30% toxicity grade 3).
作为在阿根廷开展的一项I/II期黑色素瘤硼中子俘获疗法（BNCT）临床试验的一部分，该试验由阿根廷原子能委员会（CNEA）和安吉尔·H·罗福肿瘤研究所（IOAHR）合作进行，7名患者（6名女性 - 1名男性）接受了8个疗程的治疗，覆盖位于四肢的10个解剖区域。患者的平均年龄为64岁（51 - 74岁）。治疗于2003年10月至2007年6月期间进行。所有患者均出现黑色素瘤的多处皮下皮肤转移，并接受了一次含有约14克/平方米的硼苯基丙氨酸（BPA）的输注，随后将该区域暴露于RA - 6反应堆的混合热 - 超热中子束下。正常皮肤的最大规定剂量范围为16.5至24戈瑞当量，正常组织的给药剂量范围为15.8至27.5戈瑞当量。考虑可评估的结节，总体反应率为69.3%，无变化率为30.7%。毒性是可接受的，10个可评估区域中有3个出现溃疡（毒性等级3为30%）。
